CB2 Receptor Modulators for Selective Pain Management
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current therapies fail to effectively manage all types of nociceptive and neuropathic pain, and existing treatments for pain conditions often come with adverse side effects due to nonselective activation of cannabinoid receptors.
Innovation Solution
Development of novel cannabinoid receptor 2 (CB2) modulators that selectively target CB2 receptors, which are involved in analgesia and have immunomodulatory and anti-inflammatory properties, to treat pain and immune-related disorders.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If nonselective cannabinoid receptor agonists are used to treat pain, then analgesic effect is achieved, but adverse side effects occur due to nonselective activation of CB1 and CB2 receptors
Solution Approach 1:
The patent applies segmentation by dividing the cannabinoid receptor system into two distinct targets: CB1 and CB2 receptors. The invention selectively targets only CB2 receptors while avoiding CB1 receptors, thereby segmenting the therapeutic action to achieve pain relief without the psychoactive side effects associated with CB1 activation. This is achieved through molecular design of compounds that specifically bind to CB2 receptors.
Solution Approach 2:
The patent implements local quality by creating compounds with specific molecular characteristics that confer selective affinity for CB2 receptors over CB1 receptors. The chemical structure is designed with particular substituents and functional groups (as defined in formula I with specific R1-R8 parameters) that create a localized interaction pattern matching the CB2 receptor binding site, thereby achieving selective modulation of CB2-mediated analgesia while sparing CB1 receptors from activation.
2Reliability
If CB1 receptor activation is used for pain treatment, then analgesic effect is achieved, but psychoactive side effects occur
Solution Approach 1:
The patent applies the extraction principle by isolating the therapeutic benefit (analgesia) from the harmful effect (psychoactivity) through selective receptor targeting. By extracting the CB2 receptor as the specific target and excluding CB1 receptor interaction, the invention separates the desired analgesic effect from the unwanted psychoactive side effects, achieving pain relief without intoxication or cognitive impairment.
Solution Approach 2:
The patent uses CB2-selective compounds as intermediaries to transmit the therapeutic effect without activating CB1 receptors. These compounds act as selective mediators that bind to and activate CB2 receptors located primarily in peripheral tissues and immune cells, thereby mediating analgesia and anti-inflammatory effects while avoiding the central nervous system psychoactive effects associated with CB1 activation.
3Adaptability or versatility
If existing pain therapies are used, then some pain conditions are treated, but effectiveness is limited across all nociceptive and neuropathic pain types
Solution Approach 1:
The patent applies universality by designing CB2-selective compounds with broad therapeutic potential across multiple pain conditions. The CB2 receptor is implicated in both nociceptive and neuropathic pain pathways, as well as in inflammatory and immune-mediated pain. By targeting this single receptor subtype with high selectivity, the invention creates a universal analgesic approach that may effectively treat diverse pain syndromes including arthritis, neuropathic pain, and inflammatory pain, thereby achieving both versatility and reliability.
Data Source
AI summary
The present invention relates to compounds of formula (I), or pharmaceutically acceptable salts, prodrugs, salts of prodrugs, or combinations thereof, wherein R1, R2, R3, R4, and L2, are defined in the specification, compositions comprising such compounds, and methods of treating conditions and disorders using such compounds and compositions.